Clarity Pharmaceuticals Ltd. · ASX:CU6
Clarity Pharmaceuticals — Wilsons Drug and Device Conference (October 2022)
13 slides from Clarity Pharmaceuticals's conference presentation, Oct 28, 2022
Slide 1: Wilsons Drug and Device Conference
Developing the next-generation of radiopharmaceuticals to improve treatment outcomes for children and adults with cancer Wilsons Drug and Device Conference Dr Alan Taylor, Executive Chairman Dr Colin Biggin, Chief Executive Officer 28 October 2022
Slide 2: Disclaimer
Disclaimer Introduction No representation, warranty or assurance (express or implied) is given or made in relation to any forward- This presentation has been prepared by Clarity Pharmaceuticals Ltd (ACN 143 005 341) (Clarity or the looking statement by any person (including any of the Limited Partie
Slide 3: Targeted radiopharmaceuticals are becoming a new pillar of oncology
Targeted radiopharmaceuticals are becoming a new pillar of oncology Radiopharmaceuticals are systemic agents that can be used to diagnose and treat different types of cancer Targeted radiopharmaceuticals use special targeting agents which go to specific receptors on specific cancers. Delivering radi
Slide 4: Radiopharmaceuticals: Market overview
Radiopharmaceuticals: Market overview Global Oncology Market 2021 Global Oncology Market 2031 US$286 Bn US$~25 Bn US$~1.3 Bn US$600 Bn US$6.3 Bn US$35 Bn US$ ~5 Bn US$~10 Bn Global Oncology Global radiopharmaceuticals Radio-therapeutics Radio-diagnostics 2021 2031 Global oncology market US$ 286 Bill
Slide 5: Growth drivers
Growth drivers Radiopharmaceuticals have shown significant growth potential both diagnostically and therapeutically and companies, similar to Clarity, have proven to be very profitable Positive changes have driven Big Pharma interest in the space Re-imbursement Novartis Pricing (Pluvicto >US$
Slide 6: Current industry challenges
Current industry challenges Combined with a history of Creates challenges supply issues for prescribers Additional demands on existing supply as industry grows Work to be done to convince oncologists that there is a safe, dependable and Inability to control Time sensitive reliable source of the enti
Slide 7: Clarity’s TCTs address the current industry challenges
Clarity’s TCTs address the current industry challenges Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company with a mission to develop next- generation products that improve treatment outcomes for children and adults with cancer Proprietary SAR Technology platform enables Targeted
Slide 8: Proprietary SAR Technology platform
Proprietary SAR Technology platform Theranostic radiopharmaceuticals have four main elements: a radioisotope, cage, linker and targeting ligand and are administered intravenously Radioisotope Copper isotopes used, for example, in Positron Emission Tomography (PET) Tumour imaging (64Cu) or therapy (6
Slide 9: TCTs: A robust foundation for future growth
TCTs: A robust foundation for future growth Copper-64 (half-life = 12.7 hours) Copper-67 (half life = 2.6 days) • Mass produced on cyclotrons • Optimal half-life for peptide-based therapy • Every US zip code covered from 1 location • Commercially available high powered rhodotron for • Patient flexib
Slide 10: Dual development strategy
Dual development strategy SAR Technology enables a synergistic development of stand-alone diagnostics as well as paired theranostics Diagnostics based on 64Cu Theranostics based on 64Cu/67Cu Dx revenue pays for late-stage • Broad market opportunities Tx clinical development • High precision, high ac
Slide 11: Three core product areas in clinical trials
Three core product areas in clinical trials Clarity has an active clinical development program in multiple oncology indications with unmet needs through a range of products and their applications. The SAR platform is also used in our SAR-DISCOVERY program which has significant synergies with the exi
Slide 12: Inflection points over next 12 months
Inflection points over next 12 months Dx = Diagnostics Tx = Theranostics BBN Tx 1st patient treated SECuRE BBN Tx BBN Tx US Advance to Open IND cohort 2 COBRA SABRE PSMA Phase III BBN Tx US PSMA Tx US Recruitment 50% recruitment Pivotal study complete BBN Dx US commences COBRA PSMA Dx US PSMA Dx US
Slide 13: Thank you
Thank you Contact details Dr Alan Taylor Dr Colin Biggin Executive Chairman Managing Director E: alan.taylor@claritypharm.com E: colin.biggin@claritypharm.com
Clarity Pharmaceuticals — Wilsons Drug and Device Conference (October 2022) on 6ix